Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
2(17%)
Results Posted
33%(1 trials)
Terminated
3(25%)

Phase Distribution

Ph phase_2
4
33%
Ph phase_1
2
17%
Ph not_applicable
3
25%
Ph phase_3
1
8%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(3)
Terminated(3)
Other(3)

Detailed Status

Terminated3
Completed3
unknown3
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 24 (40.0%)
Phase 31 (10.0%)
N/A3 (30.0%)

Trials by Status

recruiting217%
not_yet_recruiting18%
terminated325%
completed325%
unknown325%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
RADIATION
Total Trials
12